Login to Your Account



OF SENSE AND ANTISENSE

'Data' lot of money: Celgene's pays Nogra $710M up front for phase II Crohn's drug

By Randy Osborne
Staff Writer

Thursday, April 24, 2014
Analysts had plenty of questions but few data-driven answers about Celgene Corp.'s decision to pay $710 million up front to privately held Nogra Pharma Ltd. to develop and commercialize GED-0301, a phase III-ready, oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate to severe Crohn's disease (CD) and other indications.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription